Picture of BioLargo logo

BLGO BioLargo Income Statement

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsAdventurousSmall CapNeutral

Annual income statement for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.5161.361.862.432.53
Cost of Revenue
Gross Profit0.1930.6210.9161.231.1
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses6.418.89.5910.59.31
Operating Profit-5.9-7.43-7.72-8.03-6.78
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-9.55-10.7-11.4-9.7-6.89
Net Income After Taxes-9.55-10.7-11.4-9.7-6.89
Minority Interest
Net Income Before Extraordinary Items
Net Income-9.12-10.2-10.7-8.43-7.08
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-9.12-10.2-10.7-8.43-7.08
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.092-0.075-0.064-0.041-0.027

Or unlock with your email

Or unlock with your email